Risk of prostate carcinoma death in patients with lymph node metastasis

Cancer

Volumn 91, Issue 1, 2001, Pages 66-73

  Cheng, Liang ^a,c   Zincke, Horst ^a   Blute, Michael L ^b   Bergstralh, Erik J ^b   Scherer, Beth ^b   Bostwick, David G ^b  

^a INDIANA UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Hormonal therapy; Metastasis; Neoplasms; Prostate carcinoma; Radical prostatectomy; Treatment

Indexed keywords

DNA; HORMONE; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER GRADING; CANCER MORTALITY; CANCER STAGING; HORMONAL THERAPY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PLOIDY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA; CAUSE OF DEATH; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 0035174896     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010101)91:1<66::AID-CNCR9>3.0.CO;2-P     Document Type: Article

References (47)

1. Cancer statistics
2. The American Cancer Society National Prostate Cancer Detection Project and national patterns of prostate cancer detection and treatment
3. Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation
4. Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment: Evidence for favorable survival in patients with DNA diploid tumors
5. The role of pathologic variables and hormonal treatment after radical prostatectomy for stage D1 disease
6. Extended experience with surgical treatment of stage D1 adenocarcinoma of prostate: Significant influences of immediate adjuvant hormonal treatment (orchiectomy) on outcome
7. Stage D1 prostate cancer: A nonrandomized comparison of conservative treatment options versus radical prostatectomy
8. Cancer volume of lymph node metastasis predicts progression in prostate cancer
9. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymph adenectomy in men with node positive prostate cancer
10. Radical prostatectomy for stage D1 prostate cancer: Prognostic variable and results of treatment
11. Result of treatment of patients with stage D1 prostatic carcinoma
12. Adjuvant endocrine therapy after radical prostatectomy for stage D1 prostate carcinoma
13. Prognosis of patients with stage D1 prostate carcinoma following radical prostatectomy with and without early endocrine therapy
14. New concepts in the treatment of stage D1 adenocarcinoma of the prostate
15. Survival and quality of life of patients with stage D1 (T1-3, pN 1-2 m0) prostate cancer
16. The challenge of treating node-positive prostate cancer: An approach to resolving the questions
17. Radical prostatectomy and early adjuvant hormonal therapy for pTxN+ adenocarcinoma of the prostate
18. Grading prostate cancer
19. Evaluation of the current incidence of nodal metastasis from prostate cancer
20. Survival after radical prostatectomy
21. The National Cancer Data Base report on longitudinal observations on prostate cancer
22. Treatment options for patients with stage D1 (T0-3, N1-2, M0) adenocarcinoma of prostate
23. Combined surgery and immediate adjuvant hormonal treatment for stage D1 adenocarcinoma of the prostate: Mayo Clinic experience
24. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: A matched comparison
25. Bilateral pelvic lymphadenectomy and radical retropubic prostatectomy for adenocarcinoma of prostate with regional lymph node involvement
26. Stage D1 (T1-3, N1-3, M0) prostate cancer: A case-controlled comparison of conservative treatment versus radical prostatectomy
27. Does radical prostatectomy in the presence of positive pelvic lymph nodes enhance survival?
28. Prognostic factors in men with stage D1 prostate cancer: Identification of patients less likely to have prolonged survival after radical prostatectomy
29. Management of stage D1 adenocarcinoma of the prostate: The Johns Hopkins experience 1974-1987
30. Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients: Impact on time to progression
31. Progression in untreated carcinoma of the prostate metastatic to regional lymph nodes (stage TO to 4, N1 to 3, M0, D1)
32. Implications of volume of nodal metastasis inpatients with adenocarcinoma of the prostate
33. Prognostic significance of lymph nodal metastases in prostate cancer
34. Prospective analysis of prostate-specific markers in pelvic lymph node of patients with high-risk prostate cancer
35. Independent origin of multiple foci of prostate intraepithelial neoplasia (PIN): Comparison with matched foci of prostate cancer
36. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization
37. Allelic imbalance in the clonal evolution of prostate carcinoma
38. Evidence of independent origin of multiple tumors from prostate cancer patients
39. p53 alteration in regional lymph node metastases from prostate carcinoma: A marker for progression?
40. Dedifferentiation in metastatic progression of prostate cancer
41. Cell proliferation in prostate cancer patients with lymph node metastasis: A marker for progression
42. How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution!
43. Assessment of endpoints for clinical trials for localized prostate cancer
44. Radical prostatectomy for pathologic stage C prostate cancer: Influence of pathologic variables and adjuvant treatment of disease outcome